Concepedia

Bradley Freilich

BF

Statistics

Publications

12

Citations

2.8K

H-Index

12

Active since

2007

Affiliations

Cornell University(Current)

Kansas City VA Medical Center

Beth Israel Deaconess Medical Center

Gilead Sciences (United States)

Texas Liver Institute

Bradley Freilich is an author at Cornell University specializing in viral hepatitis, antiviral therapy, and viral hepatitis treatment.

Publications per year

2007–2020

12

Publications

12

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

Alexander Thompson, Andrew J. Muir, Mark S. Sulkowski et al. · Gastroenterology · 2010 · 723 citations · Full text

, , +17

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

David R. Nelson, James N. Cooper, Jacob Lalezari et al. · Hepatology · 2015 · 689 citations · Full text

, , +15

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Eric Lawitz, Jay Lalezari, Tarek Hassanein et al. · The Lancet Infectious Diseases · 2013 · 328 citations

, , +16

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients

Ira M. Jacobson, Robert S. Brown, Bradley Freilich et al. · Hepatology · 2007 · 306 citations · Full text

, , +17

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

Stephen A. Harrison, Zachary Goodman, Abdul Jabbar et al. · Journal of Hepatology · 2019 · 251 citations

, , +10

1–5 of 12